* Infinity Pharmaceuticals Inc INFI.OQ INFI.O is
expected
to show a rise in quarterly revenue when it reports results on
July 25 (estimated).
* The Cambridge Massachusetts-based company is expected to
report
a 1.2% increase in revenue to $518 thousand from $512 thousand
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Infinity
Pharmaceuticals
Inc is for a loss of 15 cents per share. For the same quarter
last year, the company reported a loss of 13 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Infinity
Pharmaceuticals Inc is $5, above its last closing price
of $0.78.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2022 -0.13 -0.13 -0.14 Missed -3.7
Dec. 31 2022 -0.14 -0.13 -0.13 Met 3.7
Sep. 30 2021 -0.13 -0.13 -0.12 Beat 10.8
Jun. 30 2021 -0.14 -0.14 -0.13 Beat 4.4
Mar. -0.12 -0.12 -0.15 Missed -20.2
31 2021
Dec. 31 2020 -0.16 -0.16 -0.16 Met -2.1
Sep. 30 2020 -0.15 -0.16 -0.16 Met -2.6
Jun. 30 2020 -0.20 -0.19 -0.16 Beat 16.1
This summary was machine generated July 22 at 13:28 GMT. All
figures in US dollars unless otherwise stated